ArticleMolecular biology reports2025
Evaluation of a lipid peroxidation-dependent ferroptosis RNA panel expression as a potential noninvasive biomarker in patients with nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic steatohepatitis (NASH) is a major cause of hepatocellular carcinoma (HCC) and is the fastest growing etiology of HCC worldwide. A sensitive non-invasive marker for the diagnosis, screening, or clinical monitoring of NASH-HCC, however, has yet to be established. METHODS AND
resultsWe used reverse transcription quantitative real-time PCR (RT-qPCR) to evaluate the expression of a bioinformatically-retrieved RNA panel related to lipid peroxidation-dependent ferroptosis in 193 subjects. The area under the receiver operating characteristic (ROC) curve was calculated to assess its diagnostic performance in discriminating NASH-associated HCC in NASH cases. ROC analysis indicated that the selected ferroptosis-related RNAs had various diagnostic performances. GPX4 had great potential in distinguishing NASH-associated HCC from NASH (AUC (SE) = 0.999 (0.002), P < 0.0001), which was superior to alpha-fetoprotein (AFP) and the recently developed GALAD score. Additionally, for the first time, we proposed that miR-762 has a critical role in NASH-associated HCC which can add to the unique molecular pattern of this etiology.
conclusionsOur study indicates that this RNA panel has significant superiority with respect to the current biomarkers for NASH-HCC diagnosis, and it is promising for clinical application and as a therapeutic target after further validation.
Indexed as
Identifiers
41460534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.